Semorinemab

Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23) . Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease[1].

Product Specifications

CAS Number

[2159141-27-0]

Product Name Alternative

RG 6100; RO7105705; MTAU-9937A

UNSPSC

12352203

Target

Tau Protein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/semorinemab.html

Purity

99.36

Solubility

10 mM in DMSO

Smiles

[Semorinemab]

Molecular Weight

(145.1 kDa)

References & Citations

[1]Ayalon G, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13 (593) :eabb2639.